What Policy Changes Could Mean for Biopharma
Firms may face headwinds in U.S. sales, but our fair value estimates haven't budged.
Many healthcare reforms have surfaced over the past two decades, but very few have become law as 1) the biopharma lobbying group holds significant power, 2) the government wants to avoid disrupting innovation and lifesaving medicines, 3) Republicans tend to prefer less interference with market forces, and 4) the complexity of changing drug prices makes new laws challenging to pass.
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.